A controlled trial of photochemotherapy for persistent palmoplantar pustulosis

Murray, D; Corbett, Mandy; Warin, A P

doi:10.1111/j.1365-2133.1980.tb06565.x

Cited by 63 publications

(52 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This corroborates the state ment of Murray and Warm [8] that oral psoralen is preferable to topical psoralen for PUVA treatment of PPP. This may be due to a more advantageous (deeper) distribution of psoralen in the skin during oral medication as compared to local applications, but other factors may contribute to create this differ ence.…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Suppression of Palmoplantar Pustulosis Symptoms with Oral 8-Methoxypsoralen and High-Intensity UVA Irradiation

Paul¹,

Jansén²

1983

Dermatology

View full text Add to dashboard Cite

9 patients with long-standing palmoplantar pustulosis were treated with oral 8-methoxypsoralen and high-intensity UVA irradiation (PUVA, 46.2 mW/cm²), 20 irradiations with single doses of up to 14.8 J/cm² resulted in good or excellent clearing in 4 out of 5 patients, while none of 4 patients receiving 5–6 irradiations of up to 5.2 J/cm² improved significantly. Comparison with earlier investigations leads to the conclusion that systemic PUVA is more efficient than topical PUVA in the treatment of palmoplantar pustulosis. This may result from different skin distribution of psoralen or from a more rapid decline in the photosensitivity of topically medicated skin during prolonged irradiation as compared to skin sensitized by oral psoralen administration. The use of a high-irradiance UVA source diminishes the influence of this time factor and improves patient compliance.

show abstract

Section: Discussionsupporting

confidence: 88%

“…Recently, success has been claimed for PUVA treatments, using topical [1,5,7,8. 10] and systemic application of psoralen [3,[4][5][6][7][8].…”

mentioning

confidence: 99%

Suppression of Palmoplantar Pustulosis Symptoms with Oral 8-Methoxypsoralen and High-Intensity UVA Irradiation

Paul¹,

Jansén²

1983

Dermatology

View full text Add to dashboard Cite

show abstract

“…UVA can induce clearance in approximately 40% of people with PPP 193 . Acitretin has been shown to improve disease in about two-thirds of people with PPP, but may require continued treatment after achieving remission to avoid recurrent symptoms 194, 195 .…”

Section: Pustular Psoriasis and Clinical Variantsmentioning

confidence: 99%

Autoinflammatory Pustular Neutrophilic Diseases

Naik

Cowen

2013

Dermatologic Clinics

114

View full text Add to dashboard Cite

SYNOPSIS The inflammatory pustular dermatoses constitute a spectrum of non-infectious conditions ranging from localized involvement to generalized disease with associated acute systemic inflammation and multi-organ involvement. Despite the variability in extent and severity of cutaneous presentation, each of these diseases is characterized by non-infectious neutrophilic intra-epidermal microabscesses. Many share systemic findings including fever, elevated inflammatory markers, inflammatory bowel disease and/or osteoarticular involvement, suggesting potential common pathogenic links (Figure 1). The recent discoveries of several genes responsible for heritable pustular diseases have revealed a distinct link between pustular skin disease and regulation of innate immunity. These genetic advances have led to a deeper exploration of common pathways in pustular skin disease and offer the potential for a new era of biologic therapy which targets these shared pathways. This chapter provides a new categorization of inflammatory pustular dermatoses in the context of recent genetic and biologic insights. We will discuss recently-described monogenic diseases with pustular phenotypes, including deficiency of IL-1 receptor antagonist (DIRA), deficiency of the IL-36 receptor antagonist (DITRA), CARD14-associated pustular psoriasis (CAMPS), and pyogenic arthritis, pyoderma gangrenosum, acne (PAPA). We will then discuss how these new genetic advancements may inform how we view previously described pustular diseases, including pustular psoriasis and its clinical variants, with a focus on historical classification by clinical phenotype.

show abstract

“…A few reports of PUVA therapy have been published and clearing rates of between 50 and 70%, have been obtained in different studies. Chronic scaling palmoplantar psoriasis responded much more favorably [1,7,8].…”

Section: Discussionmentioning

confidence: 99%